Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

In our industry, there exists an expectation for a facility to be purpose-built to our specifications. At the same time, regulators are keen to ensure companies demonstrate that their facilities are suitable. However, with mergers/acquisitions, as well as cost-cutting initiatives, facilities are being shut down and product lines consolidated into existing facilities—risking sub-optimal layout and design. 

The professionals tasked with reconfiguring these facilities certainly do not mean to achieve suboptimal results that fail regulatory scrutiny, but it happens more often than you would think. Retrofitting needs to be assessed with the same discipline and green-field approach as a new facility – i.e, with precision. Too often, though, a “let’s see if we can make this work” daredevil approach creeps in when the task is “just a retrofit.” 

The placement of products into facilities not initially built for purpose does not necessarily present an objectionable practice if we understand the product and process requirements, and more importantly, the impact of the proposed new product/process within the facility. 

Contamination control for both microbial and chemical cross-contamination is an often-overlooked assessment that should occur each time we plan to bring a product into a facility. It must also be a standard part of our change control process for new product introduction. The European Union has already issued instructions requiring the use of Quality Risk Management (QRM) principles to assess and control the risk of cross-contamination. These requirements are contained in the EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Part 1, Chapter 3: Premises and Equipment, and Chapter 5: Production.

The risk assessment should start with understanding the new products’ vectors of contamination, and how these can impact existing products and processes in the facility. The risk assessment should consider the current design of the facility, and how this may be sufficient (or deficient) to exclude the introduction and transmission of organisms and chemicals. This stage presents the perfect opportunity to correct deficiencies as corrections made during this phase occur before there is an adverse impact on existing operations.

The best way to truly appreciate this is to see with your own eyes real-life examples of repurposed rooms that professionals tried to “make it work”, only in retrospect the missteps they made along the way. In Part 2 of this blog (just scroll to the next blog), I recount some of these examples in the hope that they help you avoid similar difficulties. Remember, the greatest risk in repurposing an area is lacking a full understanding of the original design.


QxP Vice President Bob Ferer is a 30-year veteran in pharma. Prior to joining QxP, Bob worked with Sanofi Pasteur on a building / process train renovation. His role for Sanofi was to support the team from a compliance and regulatory aspect for the testing, qualification, and validation for all critical utilities, equipment, systems, and processes. Bob’s experience and insights have been very valuable to QxP clients. 

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023